Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes

Journal of Psychiatric Research

Volumn 62, Issue , 2015, Pages 78-83

  de Sousa, Rafael T ^a   Zanetti, Marcus V ^a   Talib, Leda L ^a   Serpa, Mauricio H ^a   Chaim, Tiffany M ^a   Carvalho, Andre F ^c   Brunoni, Andre R ^a   Busatto, Geraldo F ^a   Gattaz, Wagner F ^a   Machado Vieira, Rodrigo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Bipolar disorder; Depression; GSK3; Lithium; Neurobiology; Treatment

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CARBONATE; SERINE; ANTIDEPRESSANT AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ADULT; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; LITHIUM BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; THROMBOCYTE; BIPOLAR DISORDER; BLOOD; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PSYCHOLOGICAL RATING SCALE; STATISTICS; YOUNG ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; BLOOD PLATELETS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CARBONATE; MALE; PHOSPHORYLATION; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 84924330827     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.01.016     Document Type: Article

References (48)

1. Alimohamad H., Rajakumar N., Seah Y.H., Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005, 57:533-542.
2. Aubry J.M., Schwald M., Ballmann E., Karege F. Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation. Psychopharmacol Berl 2009, 205:419-429.
3. Barbosa I.G., Machado-Vieira R., Soares J.C., Teixeira A.L. The immunology of bipolar disorder. Neuroimmunomodulation 2014, 21:117-122.
4. Barry F.A., Graham G.J., Fry M.J., Gibbins J.M. Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function?. FEBS Lett 2003, 553:173-178.
5. Beasley C., Cotter D., Everall I. An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr Res 2002, 58:63-67.
6. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004, 101:5099-5104.
7. Benedetti F., Bernasconi A., Lorenzi C., Pontiggia A., Serretti A., Colombo C., et al. Asingle nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004, 355:37-40.
8. Benedetti F., Serretti A., Colombo C., Lorenzi C., Tubazio V., Smeraldi E. Aglycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004, 368:123-126.
9. Berk M., Berk L., Dodd S., Cotton S., Macneil C., Daglas R., et al. Stage managing bipolar disorder. Bipolar Disord 2013, 16:471-477.
10. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
11. Beurel E., Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 2006, 79:173-189.
12. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999, 96:8745-8750.
13. Chen L., Zhou W., Chen P.C., Gaisina I., Yang S., Li X. Glycogen synthase kinase-3β is a functional modulator of serotonin-1B receptors. Mol Pharmacol 2011, 79:974-986.
14. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002, 43:1158-1164.
15. de Sousa R.T., Zarate C.A., Zanetti M.V., Costa A.C., Talib L.L., Gattaz W.F., et al. Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. JPsychiatr Res 2014, 50:36-41.
16. Du J., Wei Y., Liu L., Wang Y., Khairova R., Blumenthal R., et al. Akinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A 2010, 107:11573-11578.
17. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002, 8:126-132.
18. Eom T.Y., Jope R.S. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs invivo neural precursor cell proliferation. Biol Psychiatry 2009, 66:494-502.
19. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured clinical interview for DSM-IV Axis I disorders 1995, Patient Ed., Biometrics Research, New York Psychiatric Institute, New York.
20. Forlenza O.V., Diniz B.S., Radanovic M., Santos F.S., Talib L.L., Gattaz W.F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011, 198:351-356.
21. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426.
22. Hamilton M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-62.
23. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. JNeurochem 2008, 104:1433-1439.
24. Jope R.S. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 2011, 4:16.
25. Kessing L.V., Andersen P.K. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?. JNeurol Neurosurg Psychiatry 2004, 75:1662-1666.
26. Kessing L.V., Søndergård L., Forman J.L., Andersen P.K. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008, 65:1331-1335.
27. Kozlovsky N., Belmaker R.H., Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000, 157:831-833.
28. Lachman H.M., Pedrosa E., Petruolo O.A., Cockerham M., Papolos A., Novak T., et al. Increase in GSK3beta gene copy number variation in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:259-265.
29. Ladeira R.B., Joaquim H.P., Talib L.L., Nunes P.V., Forlenza O.V. Higher proportion of inactive Gsk3β in platelets of elderly patients with bipolar disorder: an effect of treatment?. Rev Bras Psiquiatr 2013, 35:274-278.
30. Li X., Friedman A.B., Zhu W., Wang L., Boswell S., May R.S., et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 2007, 61:216-222.
31. Li X., Jope R.S. Is glycogen synthase kinase-3 a central modulator in mood regulation?. Neuropsychopharmacology 2010, 35:2143-2154.
32. Li X., Liu M., Cai Z., Wang G. Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord 2010, 12:741-752.
33. Machado-Vieira R., Manji H.K., Zarate C.A. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009, 11(Suppl.2):92-109.
34. Machado-Vieira R., Soeiro-De-Souza M.G., Richards E.M., Teixeira A.L., Zarate C.A. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry 2014, 15:84-95.
35. Martin M., Rehani K., Jope R.S., Michalek S.M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005, 6:777-784.
36. Mendes C.T., Mury F.B., de Sá Moreira E., Alberto F.L., Forlenza O.V., Dias-Neto E., et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry Clin Neurosci 2009, 259:16-22.
37. Nunes P.V., Forlenza O.V., Gattaz W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007, 190:359-360.
38. Pandey G.N., Ren X., Rizavi H.S., Dwivedi Y. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment. JPsychiatr Res 2010, 44:143-148.
39. Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007, 53:703-717.
40. Petkova E., Quitkin F.M., McGrath P.J., Stewart J.W., Klein D.F. Amethod to quantify rater bias in antidepressant trials. Neuropsychopharmacology 2000, 22:559-565.
41. Plein H., Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol 2001, 16:229-236.
42. Polter A., Beurel E., Yang S., Garner R., Song L., Miller C.A., et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010, 35:1761-1774.
43. Ryves W.J., Harwood A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001, 280:720-725.
44. Stahl S.M. The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 1977, 34:509-516.
45. Sutton L.P., Rushlow W.J. The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3. Int J Neuropsychopharmacol 2012, 15:965-979.
46. Talib L.L., Valente K.D., Vincentiis S., Gattaz W.F. Correlation between platelet and brain PLA(2) activity. Prostaglandins Leukot Essent Fatty Acids 2013, 89:265-268.
47. Zainaghi I.A., Forlenza O.V., Gattaz W.F. Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacol Berl 2007, 192:547-553.
48. Zhang F., Phiel C.J., Spece L., Gurvich N., Klein P.S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. JBiol Chem 2003, 278:33067-33077.